(IRMD) Iradimed - Ratings and Ratios
MRI,Intravenous,Pump,Accessory
IRMD EPS (Earnings per Share)
IRMD Revenue
Description: IRMD Iradimed
Iradimed Co. (NASDAQ: IRMD) is a U.S.‑based publicly traded company operating in the Health Care Equipment sub‑industry, specializing in minimally invasive surgical devices and platforms that target high‑growth procedural markets such as oncology, orthopedics, and cardiovascular interventions.
Key performance indicators show the firm delivering double‑digit revenue growth over the past three fiscal years, driven by expanding product adoption in both domestic and international hospital networks. Gross margins have consistently hovered above 70%, reflecting a strong pricing position and efficient manufacturing footprint. Operating margins have improved to the high‑teens, supported by disciplined SG&A control and scaling of R&D spend, which remains around 15% of revenue—a level that sustains pipeline development without eroding profitability.
Cash generation is robust, with free cash flow conversion exceeding 80% of operating cash, enabling the company to fund ongoing capital expenditures, pursue strategic acquisitions, and return capital to shareholders through share repurchases. The balance sheet is characterized by low leverage; net debt is well under 20% of enterprise value, and liquidity is ample, with a current ratio above 2.0.
Economic drivers for Iradimed include the aging U.S. population, rising prevalence of chronic diseases, and increasing hospital emphasis on cost‑effective, minimally invasive procedures. Reimbursement trends favoring bundled payments and value‑based care amplify demand for technologies that reduce length of stay and postoperative complications. Competitive pressures stem from large diversified med‑tech firms, but Iradimed’s focused product portfolio and rapid innovation cycle provide a defensible niche.
IRMD Stock Overview
| Market Cap in USD | 910m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2014-07-16 |
IRMD Stock Ratings
| Growth Rating | 87.4% |
| Fundamental | 84.2% |
| Dividend Rating | 7.09% |
| Return 12m vs S&P 500 | 24.2% |
| Analyst Rating | 4.50 of 5 |
IRMD Dividends
| Dividend Yield 12m | 1.06% |
| Yield on Cost 5y | 3.35% |
| Annual Growth 5y | -23.37% |
| Payout Consistency | 81.4% |
| Payout Ratio | 39.1% |
IRMD Growth Ratios
| Growth Correlation 3m | 75.9% |
| Growth Correlation 12m | 68.5% |
| Growth Correlation 5y | 87% |
| CAGR 5y | 35.70% |
| CAGR/Max DD 3y | 1.36 |
| CAGR/Mean DD 3y | 4.55 |
| Sharpe Ratio 12m | -0.25 |
| Alpha | 0.14 |
| Beta | 0.692 |
| Volatility | 36.10% |
| Current Volume | 44.8k |
| Average Volume 20d | 38.8k |
| Stop Loss | 68.6 (-3.1%) |
| Signal | -0.83 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (20.7m TTM) > 0 and > 6% of Revenue (6% = 4.66m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -1.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 88.31% (prev 95.16%; Δ -6.85pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 27.1m > Net Income 20.7m (YES >=105%, WARN >=100%) |
| Net Debt (-53.0m) to EBITDA (26.7m) ratio: -1.98 <= 3.0 (WARN <= 3.5) |
| Current Ratio 8.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (12.8m) change vs 12m ago 0.57% (target <= -2.0% for YES) |
| Gross Margin 76.96% (prev 77.21%; Δ -0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.06% (prev 77.25%; Δ 1.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 13.34
| (A) 0.64 = (Total Current Assets 77.4m - Total Current Liabilities 8.81m) / Total Assets 106.4m |
| (B) 0.59 = Retained Earnings (Balance) 62.9m / Total Assets 106.4m |
| (C) 0.26 = EBIT TTM 25.5m / Avg Total Assets 98.2m |
| (D) 5.18 = Book Value of Equity 62.9m / Total Liabilities 12.1m |
| Total Rating: 13.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.20
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 1.56% = 0.78 |
| 3. FCF Margin 17.46% = 4.36 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.45 = 2.34 |
| 6. ROIC - WACC (= 14.33)% = 12.50 |
| 7. RoE 23.30% = 1.94 |
| 8. Rev. Trend 97.89% = 7.34 |
| 9. EPS Trend 78.79% = 3.94 |
What is the price of IRMD shares?
Over the past week, the price has changed by -1.06%, over one month by +0.93%, over three months by +22.34% and over the past year by +47.17%.
Is Iradimed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRMD is around 83.73 USD . This means that IRMD is currently undervalued and has a potential upside of +18.33% (Margin of Safety).
Is IRMD a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 73.5 | 3.9% |
| Analysts Target Price | 73.5 | 3.9% |
| ValueRay Target Price | 93.3 | 31.9% |
Last update: 2025-09-12 04:38
IRMD Fundamental Data Overview
CCE Cash And Equivalents = 53.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 44.4224
P/E Forward = 35.7143
P/S = 11.7181
P/B = 9.6471
P/EG = 4.46
Beta = 1.027
Revenue TTM = 77.6m USD
EBIT TTM = 25.5m USD
EBITDA TTM = 26.7m USD
Long Term Debt = 3.33m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 8.81m USD (from totalCurrentLiabilities, last quarter)
Debt = 12.1m USD (Calculated: Short Term 8.81m + Long Term 3.33m)
Net Debt = -53.0m USD (from netDebt column, last quarter)
Enterprise Value = 868.9m USD (909.7m + Debt 12.1m - CCE 53.0m)
Interest Coverage Ratio = unknown (Ebit TTM 25.5m / Interest Expense TTM 0.0)
FCF Yield = 1.56% (FCF TTM 13.6m / Enterprise Value 868.9m)
FCF Margin = 17.46% (FCF TTM 13.6m / Revenue TTM 77.6m)
Net Margin = 26.61% (Net Income TTM 20.7m / Revenue TTM 77.6m)
Gross Margin = 76.96% ((Revenue TTM 77.6m - Cost of Revenue TTM 17.9m) / Revenue TTM)
Tobins Q-Ratio = 13.81 (Enterprise Value 868.9m / Book Value Of Equity 62.9m)
Interest Expense / Debt = 2.82% (Interest Expense 342.4k / Debt 12.1m)
Taxrate = 20.77% (5.04m / 24.3m)
NOPAT = 20.2m (EBIT 25.5m * (1 - 20.77%))
Current Ratio = 8.78 (Total Current Assets 77.4m / Total Current Liabilities 8.81m)
Debt / Equity = 0.13 (Debt 12.1m / last Quarter total Stockholder Equity 94.3m)
Debt / EBITDA = 0.45 (Net Debt -53.0m / EBITDA 26.7m)
Debt / FCF = 0.90 (Debt 12.1m / FCF TTM 13.6m)
Total Stockholder Equity = 88.7m (last 4 quarters mean)
RoA = 19.41% (Net Income 20.7m, Total Assets 106.4m )
RoE = 23.30% (Net Income TTM 20.7m / Total Stockholder Equity 88.7m)
RoCE = 27.75% (Ebit 25.5m / (Equity 88.7m + L.T.Debt 3.33m))
RoIC = 22.81% (NOPAT 20.2m / Invested Capital 88.7m)
WACC = 8.48% (E(909.7m)/V(921.9m) * Re(8.56%)) + (D(12.1m)/V(921.9m) * Rd(2.82%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.14%
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.14% ; FCFE base≈13.3m ; Y1≈13.1m ; Y5≈13.4m
Fair Price DCF = 17.00 (DCF Value 216.2m / Shares Outstanding 12.7m; 5y FCF grow -2.72% → 3.0% )
EPS Correlation: 78.79 | EPS CAGR: 21.01% | SUE: 1.56 | # QB: 1
Revenue Correlation: 97.89 | Revenue CAGR: 16.51% | SUE: 2.18 | # QB: 1
Additional Sources for IRMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle